|This message contains images. If you don't see images, click here to view.|
Advertise in this news brief.
We are pleased to announce the brand new ASHI University — wait until you see the information available at your fingertips! ASHI U is a great way to earn Continuing Education Credits online by reading the content in the modules and taking the quizzes. ASHI members have free access to modules and quizzes!
Not a Member? Join today!
Now is the time to renew your 2015 ASHI Membership online
Doing so today so will help to avoid interruption accessing the ASHI Quarterly & ASHI-U for continuing education credits. Your Human Immunology subscription can also be renewed at this time. Renew Now.
2015 ASHI Proficiency Testing Program
ASHI is pleased to announce the 13th year of its comprehensive proficiency testing program. 2015 Brochures are available for online ordering. Please visit the Proficiency Testing Program page on our website
For further information, please contact Cecilia Blair, at the ASHI central office at firstname.lastname@example.org
Urgent — Public Comments on 18 New OPTN/UNOS Proposals due Friday, Dec. 5
The Organ Transplant Section of your ASHI National Clinical Affairs Committee (NCAC) has reviewed the proposals and prepared comments for three of the proposals that directly affect our laboratories.
Proposal #5 relates to requirements for centers involved with Vascularized Composite Allografts (VCA), Proposal #15 has some "quick fix" policy rewrites and, most importantly, Proposal #7 - Proposed Changes in the OPTN Bylaws Governing Histocompatibility Laboratories. Click here
to view the comments submitted on behalf of ASHI’s NCAC, however it is very important that each of you review the proposals yourselves and submit your own comments. All submitted comments are reviewed and the comments of any one individual count as much as those from any large organization.
Click here to review the proposals and send your own comments by December 5th.
An Exhibitor's Experience at the 2014 ASHI Annual Meeting
One of our exhibitors at the 2014 Annual Meeting in Denver had such a great time they wanted to share all their excitement. They made a video of their ASHI experience! If you have photos, video clips or testimonials you would like to share from your annual meeting experience, please send them to email@example.com.
ASHI's 5K Fun Run/Walk
Participants came together in Denver to raise awareness surrounding the life saving importance of organ donation. We are proud to announce that ASHI raised $2,350 from the second annual “Run for a Life” and this will be donated to the American Transplant Foundation.
Brian Michael Susskind (1953-2014)
Brian Susskind, Ph.D. unexpectedly passed away at home on Nov. 21, 2014. Brian was born in Florida in 1953. He received his B.A. in 1974 from The University of South Florida, his M.S. in 1976 and his Ph.D. in 1979 both from Louisiana State University. He became a Research Fellow in The Department of Biochemistry at L.S.U. Medical Center from 1979-1980. In 1981 he joined The Sloan Kettering Institute for Cancer Research as a Post-Doctoral Fellow and published several important articles dealing with cellular immune regulation in human cancer. Following his fellowship he was recruited in 1982 as an Assistant Professor in the Departments of Surgery and Microbiology at The Medical College of Virginia where he continued his research in cellular immune regulation and rose to the rank of Associate Professor. In 1991, he moved to Dr. Mohanakumar’s Laboratory at Washington University School of Medicine in St. Louis. In this capacity, he also received training in histocompatibility at the HLA Laboratory at Barnes-Jewish Hospital. In 1995, he was recruited by Prof. Ron Kerman, Department of Surgery and HLA Laboratories at The University of Texas Medical School and became a Diplomate of The American Board of Histocompatibility and Immunogenetics. In 1998 Brian relocated to Chicago and assumed the HLA Laboratory Director position at The Loyola University Medical Center Transplantation Program. Brian was recruited as the HLA Laboratory Director at The University of Cincinnati/Blood Bank and in 2008 he moved to Dallas, Texas to assume the position of HLA Laboratory Director of The Annette and Harold Simmons Transplant Institute. Brian was passionate about his work, both clinical and research and was an active member of ASHI and The Laboratory Director’s Forum. In addition to his scientific talents, Brian was a devoted husband and father. He had many friends in ASHI and in the Immunology community who cherished his company and will certainly miss him.
Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry
We have calculated six-locus high resolution HLA A∼C∼B∼DRB3/4/5∼DRB1∼DQB1 haplotype frequencies using all Be The Match® Registry volunteer donors typed by DNA methods at recruitment. Mixed resolution HLA typing data was inputted to a modified expectation–maximization (EM) algorithm in the form of genotype lists generated by interpretation of primary genomic typing data to the IMGT/HLA v3.4.0 allele list. The full cohort consists of 6.59 million subjects categorized at a broad race level. Overall 25.8 percent of the individuals were typed at the C locus, and 5.2 percent typed at the DQB1 locus, while all individuals were typed for A, B, DRB1.
Role of anti-vimentin antibodies in allograft rejection
Production of anti-vimentin antibodies (AVA) after solid organ transplantation are common. Although classically thought to be expressed mainly within the cytosol, recent evidence demonstrates that extracellular or cell surface expression of vimentin is not unusual. This review examines the evidence to assess whether AVA contribute to allograft pathology. Clinical studies suggest that AVA are associated with cardiac allograft vasculopathy in heart transplant recipients. Studies in non-human primates confirm that production of AVA after renal and heart transplantation are not inhibited by Cyclosporine. Experimental studies have demonstrated that mice pre-immunized with vimentin undergo accelerated acute rejection and vascular intimal occlusion of cardiac allografts.
MISS AN ISSUE OF ASHI INSIGHTS? |
Click here to visit the ASHI Insights archive page.
Immune system offers clues to cancer treatment
In the quest to develop personalized cancer therapies, researchers are increasingly examining an individual's immune response to cancer to find ways to tailor treatments. The shift comes with the emergence of therapies designed to unleash the immune system on cancer cells. Five studies in the Nov. 27 issue of Nature turn to the immune system to investigate which patients are likely to respond to cancer drugs that inhibit the activity of a protein called PD-1, and how tumors trigger immune responses. The approach is in contrast to earlier attempts at personalized therapies that focused on the tumor itself.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063